GleamWall
中文EN

RLYB Rallybio Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1739410 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-32.0%
TTM net income YoY289.2%
TTM EPS YoY145.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-5,580.9%
Net margin6,177.4%
FCF margin—
EBITDA margin-5,579.0%

Returns

ROE34.5%
ROA32.8%
ROIC (approx.)-149.0%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets3.4%
Debt / equity0.00x
Current ratio28.87x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.16x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$858,000$636,000
R&D expense$19.60M$41.51M
SG&A expense$14.32M$19.62M
Operating income-$33.06M-$60.50M
Pretax income-$8.98M-$55.54M
Income tax$0$0
Net income-$8.98M-$57.77M
EBITDA-$32.97M-$60.37M
EPS (basic)-1.59-10.61
EPS (diluted)-1.59-10.61
Weighted avg. shares (diluted)5.63M5.44M
Balance sheet
Cash & equivalents$31.37M$13.90M
Short-term investments$23.36M$51.61M
Current assets$61.25M$67.84M
PP&E, net$23,000$115,000
Total assets$62.26M$68.11M
Current liabilities$4.22M$6.24M
Total liabilities$4.30M$6.45M
Shareholders' equity$57.96M$61.65M
Shares outstanding5.28M5.19M
Cash flow statement
Operating cash flow-$29.81M-$49.28M
Capital expenditure—$0
Free cash flow—-$49.28M
Investing cash flow$47.27M$33.49M
Financing cash flow$16,000$5.20M
Depreciation & amortization$92,000$131,000
Stock-based compensation$5.31M$7.99M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.